-
Liquid Thyroxine Improves Outcomes in Hypothyroid Patients with Small Intestinal Bacterial Overgrowth and Irritable Bowel Syndrome Endocr. Pract. (IF 4.2) Pub Date : 2024-03-13 Brittany Bohinc Henderson MD, Shelby P. Smith BS, Marlena E. Mengelkamp BS, Emma Kate Rhymer BS, Kensi N. Gray BS, Abigail G. Jackson BS, Samantha F. Henry BS, Stacey Chuang BA, Erin H. Stavrakas DNP FNP-C, Olivia M. Blair PA-C MAPS, Melissa Heaps MSN APRN NP-C
Malabsorption of levothyroxine (LT4) is often seen in patients with hypothyroidism and gastrointestinal (GI) conditions. Our study was designed to establish the prevalence of small intestinal bacterial overgrowth (SIBO) in patients with hypothyroidism and irritable bowel syndrome (IBS), and to demonstrate that liquid LT4 is more consistently absorbed vs. tablet, leading to improvement in thyroid and
-
A Comprehensive Review of Empty Sella and Empty Sella Syndrome Endocr. Pract. (IF 4.2) Pub Date : 2024-03-12 Michelle D. Lundholm MD, Divya Yogi-Morren MD
Incidental radiographic findings of an empty sella are prevalent in up to 35% of the general population. While empty sella was initially considered clinically insignificant, a subset of patients exhibits endocrine or neuro-ophthalmologic manifestations which are diagnostic of empty sella syndrome (ESS). Recent studies suggest that more patients are affected by ESS than previously recognized, necessitating
-
Effect of sodium-glucose cotransporter 2 inhibitors on 24-hour ambulatory blood pressure in patients with type-2 diabetes and hypertension: an updated meta-analysis. Endocr. Pract. (IF 4.2) Pub Date : 2024-03-12 Fizza Iqbal, Muhammad Hamza Shuja, Laraib Azam, Marium Amjad, Kashish Zehra Manjee, Hurriyah Ramzan, Taha Sharif, Ayesha Shoaib, Amber Tahir, Satesh Kumar, Mahima Khatri, Giustino Varrassi, Tamam Mohamad MD
-
Correlation Between Impaired Sensitivity to Thyroid Hormones and Serum Uric Acid in Female Patients with Obesity and After Laparoscopic Sleeve Gastrectomy Endocr. Pract. (IF 4.2) Pub Date : 2024-03-11 Xin Wen, Hui You, Lu Wei, Junwei Guo, Lili Su, Lu Wang, Manna Zhang, Hang Sun, Haibing Chen, Le Bu, Shen Qu
An alterable risk factor for hyperuricemia is obesity. Additionally, obese persons may have a moderate form of acquired resistance to thyroid hormones. Thyrotropin (TSH), thyroid hormones, and obesity all interact subtly. However, the connection between thyroid hormone sensitivity and hyperuricaemia in obese patients both before and after laparoscopic sleeve gastrectomy (LSG) has not yet been clarified
-
Follow-up and Outcomes of 186 Patients With Follicular Cell–Derived Thyroid Cancer Seen at a Referral Center by One Thyroidologist in 2015 Endocr. Pract. (IF 4.2) Pub Date : 2024-03-08 Vahab Fatourechi MD
To study the profile, management, and outcomes of follicular cell–derived thyroid cancer (FCDTC) before publication of the 2016 American Thyroid Association guidelines recommending less aggressive thyroid cancer procedures. Patients with FCDTC were seen by one thyroidologist at Mayo Clinic during the 2015 calendar year. Patients underwent surgical procedures for FCDTC in 2015 or earlier at the Mayo
-
Imaging Characteristics and Interpretation Strategy for Renal Hyperparathyroidism: A Retrospective 4-Dimensional Computed Tomography Study Endocr. Pract. (IF 4.2) Pub Date : 2024-03-06 Yu-Fen Wang MD, Ting-Chun Kuo MD, Ming-Hsun Wu MD PhD, Chung-Wei Lee MD PhD
Parathyroidectomy treats uncontrolled renal hyperparathyroidism (RHPT), requiring identification of all glands. Three types of enhancement are proposed. Type A lesions have higher arterial phase attenuation than the thyroid, type B lesions lack higher arterial phase attenuation but have lower venous phase attenuation, and type C lesions have neither higher arterial phase attenuation nor lower venous
-
Early Structural, Biochemical, and Metabolic Responses to Anlotinib in Patients With Progressive Radioactive Iodine Refractory Differentiated Thyroid Cancer Endocr. Pract. (IF 4.2) Pub Date : 2024-03-04 Di Sun, Xin Zhang MD, Yuqing Sun, Zhuanzhuan Mu, Hao Wang MD, Yingqiang Zhang, Jun Liang MD, Yansong Lin MD PhD
We aimed to assess the early efficacy of anlotinib in patients with progressive radioactive iodine refractory differentiated thyroid cancer at the structural, biochemical, and metabolic levels. Ten eligible patients were prospectively enrolled to receive anlotinib. Their responses were assessed for 6 weeks. Apart from the structural response according to Response Evaluation Criteria in Solid Tumors
-
Pros of Inpatient Sodium Glucose Cotransporter-2 Inhibitor Use Endocr. Pract. (IF 4.2) Pub Date : 2024-02-29 Karina G. Romo MD, Roma Gianchandani MD
Sodium-glucose-cotransporter 2 (SGLT-2) inhibitors are widely used for diabetes management especially because their effects go beyond glucose control. More recently, their indications and usage have expanded to heart failure (HF) and renal dysfunction therapy in patients both with and without diabetes. Beneficial effects, especially for HF readmission, accrue very early in their treatment trajectory
-
Low Rates of Screening for Hypercortisolism Among Patients With Severe Insulin Resistance Requiring U-500 Insulin Endocr. Pract. (IF 4.2) Pub Date : 2024-02-13 Kenda Alkwatli MD, Alimitha Kodali MD, Kevin M. Pantalone DO
-
Bridging and Validation of the Specific Graves Ophthalmopathy Quality of Life Questionnaire With Health State Utility Values Endocr. Pract. (IF 4.2) Pub Date : 2024-02-08 Terry J. Smith MD, Kimberly Cockerham MD, Naina Barretto PhD, Alex Hirst PhD, Louisa Oliver MS, Ashley Enstone MS, Giulia Brandolini MS, Stephanie D. Taylor PhD, Robert J. Holt PharmD MBA
In thyroid eye disease (TED), inflammation and expansion of orbital muscle and periorbital fat result in diplopia and proptosis, severely impacting patient quality of life (QOL). The reported health state utility (HSU) scores, which are QOL measures, allow quantification of TED impact and improvement with therapies; however, no current QOL instrument has been validated with HSU scores for TED. Here
-
Using Bedside Spectral Doppler Ultrasound for the Assessment of Patients with Thyrotoxicosis Endocr. Pract. (IF 4.2) Pub Date : 2024-02-07 Michael Morkos, Karishma Datla Raju, Katherine Ibrahim
To assess the bedside utility of spectral Doppler ultrasound (SDUS) in the initial evaluation of patients presenting with thyrotoxicosis. This is a retrospective cross-sectional study of patients diagnosed with thyrotoxicosis at an academic outpatient endocrinology clinic from August 2019 to November 2022. The thyroid arteries' peak systolic velocities (PSV) were measured bilaterally using SDUS. PSV
-
Team-based care for thyroid cancer: What is the role for the primary care physician? Endocr. Pract. (IF 4.2) Pub Date : 2024-02-06 Archana Radhakrishnan, Megan R. Haymart
Abstract not available
-
SGLT2 inhibitors reduce the risk of hospitalization for heart failure and amputation rate compared with incretin-based therapy in patients with diabetic foot disease: A nationwide population-based study Endocr. Pract. (IF 4.2) Pub Date : 2024-02-06 Yi-Hsuan Lin, Chia-Hung Lin, Yu-Chih Lin, Yu-Yao Huang, An-Shun Tai, Shih-Chen Fu, Sheng-Hsuan Lin
Major adverse cardiovascular events (MACEs) outcomes associated with Sodium-glucose co-transporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) therapies remain unclear in patients with type 2 diabetes and newly diagnosed diabetic foot complications (DFCs). This study examined the impact of SGLT2i and GLP-1 RA use on the rates of MACE and amputations in type 2 diabetes
-
Treatment Sequence for Osteoporosis Endocr. Pract. (IF 4.2) Pub Date : 2024-02-02 Felicia Cosman MD, Bente Langdahl MD PhD DMSc, Benjamin Z. Leder MD
Osteoporosis is a chronic progressive disease that requires lifelong monitoring and treatment. Sequencing from one treatment to another at different ages and stages of disease is an approach that can maximize benefits and avoid potential risks from long-term treatment with a single agent. This article reviews clinical trial data in postmenopausal women that evaluate the effects of antiresorptive agents
-
Clinical Characteristics and Management of Cosecreting Thyroid Stimulating Hormone or Prolactin Pituitary Growth Hormone Adenomas: A Case-Control Study Endocr. Pract. (IF 4.2) Pub Date : 2024-02-02 Caiyan Mo, Han Chen, Jian Xu, Ying Guo, Yao Wang, Zheng Li, Tao Tong, Songbai Gui, Liyong Zhong
Cosecreting thyroid stimulating hormone (TSH) or prolactin (PRL) in patients with pituitary growth hormone (GH) adenomas has been rarely reported. Our study aimed to elucidate their clinical characteristics. We retrospectively collected data of 22 cases of cosecreting GH and TSH pituitary adenomas [(GH+TSH)oma] and 10 cases of cosecreting GH and PRL pituitary adenomas [(GH+PRL)oma] from Beijing Tiantan
-
Elite Cyclists with Type 1 Diabetes Show Acceptable Glycemic Excursions During a Time-Trial Performance Under High-Definition Transcranial Direct Current Stimulation Endocr. Pract. (IF 4.2) Pub Date : 2024-02-01 Roberto Codella PhD, Gabriele Gallo MS, Andrea Meloni MS, Livio Luzi MD, Luca Filipas PhD
To evaluate the effects of bilateral dorsolateral prefrontal cortex high-definition transcranial direct current stimulation (HD-tDCS) on glycemic excursions during a time-trial performance in elite cyclists with type 1 diabetes (T1D). In a double-blind, randomized crossover order, 9 elite cyclists with T1D (no complications) underwent either HD-tDCS (F3 and F4) or control (SHAM) and completed a constant-load
-
Radioactive Iodine Therapy of Graves’ Disease in Patients Pretreated With Methimazole Without Radioiodine Uptake for Dose Estimation Endocr. Pract. (IF 4.2) Pub Date : 2024-02-01 Dan V. Mihailescu MD, Christine Hoscheit MD, Leon Fogelfeld MD
To assess response predictors to radioactive iodine (RAI) therapy without using thyroid uptake for dose estimate in patients pretreated with methimazole. Retrospective analysis was performed of patients with Graves’ disease treated with RAI doses determined without using uptake studies. In 242 patients (median age, 41.9 years; 66.1% female), initial mean free thyroxine (FT4) level was 4.7 ng/dL with
-
Safety and Efficacy of Insulins in Critically Ill Patients Receiving Continuous Enteral Nutrition Endocr. Pract. (IF 4.2) Pub Date : 2024-02-01 Kevin Ni MD PhD, R. Matthew Hawkins PA, Heather L. Smyth PhD, Stacey A. Seggelke CNS DNP, Joanna Gibbs PA, Mark C. Lindsay NP, Laura K. Kaizer MPH, Cecilia C. Low Wang MD
There is a relative lack of consensus regarding the optimal management of hyperglycemia in patients receiving continuous enteral nutrition (EN), with or without a diagnosis of diabetes. This retrospective study examined 475 patients (303 with known diabetes) hospitalized in critical care setting units in 2019 in a single center who received continuous EN. Rates of hypoglycemia, hyperglycemia, and glucose
-
Effect of Christmas Holidays on Type 1 Diabetes Mellitus in Users of Glucose Flash Systems Endocr. Pract. (IF 4.2) Pub Date : 2024-02-01 Fernando Sebastian-Valles MD, Jose A. Arranz Martin MD PhD, Julia Martínez-Alfonso MD, Jessica Jiménez-Díaz MD, Iñigo Hernando Alday MD, Victor Navas Moreno MD, Teresa Armenta Joya MD, Maria del Mar Fandiño García MD, Gisela L. Román Gómez MD, Jon Garai Hierro MD, Luis E. Lander Lobariñas MD, Purificación Martinez de Icaya MD PhD, Miguel A. Sampedro-Nuñez MD PhD, Vicente Martínez-Vizcaíno MD PhD, Mónica
Christmas holidays can impact weight and glycemic control in type 2 diabetes, but their effect on type 1 diabetes (T1D) remains understudied. This study assessed how Christmas holidays affect individuals with T1D who use flash continuous glucose monitoring systems. This retrospective study involved 812 adults diagnosed with T1D recruited from 3 hospitals. Clinical, anthropometric, and socioeconomic
-
Info for Readers/Subscription page Endocr. Pract. (IF 4.2) Pub Date : 2024-01-29
Abstract not available
-
-
-
Discriminatory Value of Steroid Hormones on Polycystic Ovary Syndrome and Clustering of Hyperandrogenism and Metabolic Factors Endocr. Pract. (IF 4.2) Pub Date : 2024-01-18 Zheng Wang MD PhD, Martijn Van Faassen PhD, Henk Groen MD PhD, Astrid E.P. Cantineau MD PhD, Anne Van Oers MD PhD, Anna Van der Veen MD, James M. Hawley PhD, Brian G. Keevil PhD, Ido P. Kema PhD, Annemieke Hoek MD PhD
We determined (1) if 11-oxygenated androgens better identify polycystic ovary syndrome (PCOS) diagnosis in women with obesity compared to total or free testosterone (T) and free androgen index; (2) how biochemical hyperandrogenism and metabolic factors cluster in a cohort of women with infertility and obesity. Women with obesity and PCOS comprised the study group ( = 132). Ovulatory women with obesity
-
Pubertal Status at the Time of Fertility Preservation in Transgender Girls Endocr. Pract. (IF 4.2) Pub Date : 2024-01-18 Mabel Yau MD, Neha R. Malhotra MD, John Steever MD, Eva Baldisserotto CPNP-PC, Cathy Lin MS, Ralph Fader MD, Matthew Oransky PhD, Joshua D. Safer MD
Puberty blockade and gender-affirming hormone therapy can impair fertility. Counseling on fertility preservation is important before initiation of therapy. Our study aimed to assess Tanner staging and the presence of virilizing secondary sex characteristics at the time of sperm collection and correlate the viability of sperm with the Tanner staging and degree of virilization. A retrospective chart
-
Safety-Net Primary Care and Endocrinology Clinicians’ Knowledge and Perspectives on Screening for Nonalcoholic Fatty Liver Disease: A mixed methods evaluation Endocr. Pract. (IF 4.2) Pub Date : 2024-01-05 Kathryn L. Fantasia, Kirsten Austad, Arpan Mohanty, Michelle T. Long, Allan Walkey, Mari-Lynn Drainoni
Objective Clinical guidelines have expanded indications for nonalcoholic fatty liver disease (NAFLD) screening to type 2 diabetes mellitus and obesity, conditions common in populations that receive care in urban, safety-net settings. This study sought to evaluate safety-net primary care and endocrine clinician knowledge of NAFLD, identify barriers and facilitators to screening, and examine perspectives
-
Endocrine Disruptors and Metabolic Changes: Impact on Puberty Control Endocr. Pract. (IF 4.2) Pub Date : 2024-01-06 Marcela Peralta MD, Fernando Lizcano MD PhD
-
Molecular Profiling for Bethesda III to VI Nodules: Results of a Multicenter International Retrospective Study Endocr. Pract. (IF 4.2) Pub Date : 2024-01-05 Grégoire B. Morand MD MSc, Idit Tessler MD, Maxine Noik MD, Josh Krasner MD, Tzahi Yamin MD, Marc P. Pusztaszeri MD, Galit Avior MD, Richard J. Payne MD MSc FRCSC
Molecular testing is a well-established tool that assists in the management of thyroid nodules. We describe our experience using molecular testing of thyroid nodules with Bethesda III to VI cytology. This is a retrospective multicenter, multinational study of thyroid nodules that underwent preoperative molecular profiling with / or between 2015 and 2022. The clinical characteristics and mutational
-
Predicting Osteoporotic Fracture in Patients With Early-Stage Diabetic Kidney Disease Using a Radiomic Model: A Longitudinal Cohort Study Endocr. Pract. (IF 4.2) Pub Date : 2024-01-05 Youyuan Gao MD, Jianya Gao MD, Yunting Wang MD, Hua Gan PhD
There is an urgent need for effective predictive strategies to accurately evaluate the risk of fragility fractures in elderly patients in the early stages of diabetic kidney disease (DKD). This longitudinal cohort study included 715 older patients in the early stages of DKD diagnosed between January 2015 and August 2019. Patients were randomly allocated to a training cohort ( = 499) and a validation
-
Ablation Rates and Long-Term Outcome Following Low-Dose Radioiodine for Differentiated Thyroid Cancer in the West of Scotland: A Retrospective Analysis Endocr. Pract. (IF 4.2) Pub Date : 2024-01-05 Kathryn Graham MB ChB BSc MRCP FRCR PhD, Fay Tough MB ChB MRCP FRCR, Helena Belikova MB ChB MRCP FRCR, Irene Wotherspoon RN BSc MSc SPQ, David Colville MB ChB MRCP, Nicholas Reed MB ChB MRCP FRCR
Low-dose radioiodine is an accepted means of remnant ablation in patients with low- to intermediate-risk differentiated thyroid cancer (DTC) based on the results of several phase III trials. We evaluated the rate of ablation success and long-term recurrence outcomes in the first 3 years of implementing this practice at our institution. Patients who received 1.1 to 1.2 gigabecquerel (30 millicurie)
-
Survival Outcomes of Medullary Thyroid Cancer With and Without Amyloid Deposition Endocr. Pract. (IF 4.2) Pub Date : 2024-01-05 Eman Toraih MD PhD, Mohammad Hussein MD, Allison Anker BS, Solomon Baah BS, Dylan Pinion BS, Jessan Jishu MS, Salmanfaizee Sadakkadulla BS, Madeline Case BS, Alexandra LaForteza MS, Krzysztof Moroz MD, Emad Kandil MD
Amyloid deposition within tumor stroma is a distinctive histologic feature of medullary thyroid cancer (MTC). However, its prognostic significance remains uncertain. We aimed to elucidate the impact of amyloid status on survival outcomes in a large cohort. The Surveillance, Epidemiology, and End Results registry was queried to identify patients diagnosed with MTC from 2000 to 2019. Patients with amyloid-positive
-
Primary Hyperparathyroidism: Assessment of the Effects of Parathyroidectomy Using Dual X-Ray Absorptiometry, Trabecular Bone Score, and Dual X-Ray Absorptiometry–Based Three-Dimensional Modeling Endocr. Pract. (IF 4.2) Pub Date : 2024-01-05 Rosa Arboiro-Pinel MD PhD, Ignacio Mahillo-Fernández PhD, Manuel Díaz-Curiel MD PhD
This study aimed to evaluate the bone microstructure to determine whether curative surgery of primary hyperparathyroidism produces changes in bone mineral density (BMD), trabecular bone score (TBS), and three-dimensional (3D) dual x-ray absorptiometry (DXA) parameters and whether these changes are comparable. We retrospectively studied 85 patients (60 women and 25 men, 60.4 ± 12.5 years) diagnosed
-
Info for Readers/Subscription page Endocr. Pract. (IF 4.2) Pub Date : 2024-01-02
Abstract not available
-
-
-
Surveillance imaging strategies for pituitary adenomas: when, how frequent and when to stop Endocr. Pract. (IF 4.2) Pub Date : 2023-12-29 Kevin C.J. Yuen, Luma Ghalib, Michael Buchfelder, Jeremy Hughes, Fabienne Langlois, Mark E. Molitch
Magnetic resonance imaging is the mainstay imaging modality of choice in the assessment, treatment planning and follow-up of pituitary adenomas (PAs). Pituitary adenomas are discovered incidentally during imaging for a variety of unrelated conditions, because of clinical symptoms related to mass effects on the adjacent structures, or during work up for functional alterations of the adenoma. Imaging
-
Assessing the Frequency of Deferrable Thyroid Nodule Biopsies to De-escalate Low-Value Care Endocr. Pract. (IF 4.2) Pub Date : 2023-12-29 Maya Alexis BA, Sara P. Ginzberg MD MSHP, Jacqueline M. Soegaard Ballester MD MBMI, Susan J. Mandel MD MPH, Jill E. Langer MD, Rachel R. Kelz MD MSCE MBA, Heather Wachtel MD
Thyroid nodules are common, yet fewer than 1 in 10 harbors malignancy. When present, thyroid cancer is typically indolent with excellent survival. Therefore, patients who are not candidates for thyroid cancer treatment due to comorbid disease may not require further thyroid nodule evaluation. The goal of this study was to determine the rate of deferrable thyroid nodule biopsies in patients with limited
-
Corrigendum to ‘Clinical Characteristics of 28 Patients with Diabetes and COVID-19 in Wuhan, China’ [Endocrine Practice (2020) 668-674] Endocr. Pract. (IF 4.2) Pub Date : 2023-12-22 Fen Wang, Yan Yang, Kun Dong, Yongli Yan, Shujun Zhang, Huihui Ren, Xuefeng Yu, Xiaoli Shi
Abstract not available
-
Elevated TSH Levels: A Database Study of General Practitioners’ Course of Action Endocr. Pract. (IF 4.2) Pub Date : 2023-12-19 Levy Jäger, Jakob M. Burgstaller, Stefan Zechmann, Oliver Senn, Thomas Rosemann, Stefan Markun
Objective To investigate general practitioners’ course of action after detection of elevated TSH levels regarding repeat testing, direct levothyroxine replacement, or neither. Methods We conducted a retrospective study of adults without prior evidence of thyroid disease and with a first detection of elevated TSH levels from January 1, 2015, to December 31, 2020, using data from electronic medical records
-
A Review of Incretins Therapies Approved and in Late-Stage Development for Overweight and Obesity Endocr. Pract. (IF 4.2) Pub Date : 2023-12-18 Ashwin Kanna Chetty, Ebne Rafi, Natalie J. Bellini, Natalie Buchholz, Diana Isaacs
Objective To review clinical trial data for incretin therapies approved or in late-stage development for overweight or obesity, along with clinical implications of these therapies and future directions. Methods We searched for clinical trials involving incretin therapies studied specifically for overweight or obesity in ClinicalTrials.gov and PubMed through November 2023. The findings are summarized
-
Localization of ectopic hyperparathyroidism: ultrasound versus 99mTc-sestamibi, 4D-CT, and 11C-choline PET/CT Endocr. Pract. (IF 4.2) Pub Date : 2023-12-18 Song Fang, Qing-Li Zhu, Yi-Min Liu, Zhu-Hua Zhang, Ou Wang, Xiao-Ping Xing, Ya Hu, Quan Liao, He Liu, Jian-Chu Li, Yu-Xin Jiang
Objective To investigate the usefulness of ultrasound (US) for the localization of ectopic hyperparathyroidism and compare it with 99mTc-sestamibi (99mTc-MIBI), 4D-CT, and 11C-choline PET/CT. Methods Of the 527 patients with surgically confirmed primary hyperparathyroidism, 79 patients with ectopic hyperparathyroidism were enrolled. The diagnostic performance of US, 99mTc-MIBI, US+MIBI, 4D-CT, and
-
Identifying Complete Atypical Femur Fractures in Adults with Bisphosphonate Exposure Endocr. Pract. (IF 4.2) Pub Date : 2023-12-16 Joan C. Lo, Christopher D. Grimsrud
Abstract not available
-
The Clinical Utility of 68Ga-DOTATATE PET scanning in Medullary Thyroid Cancer Endocr. Pract. (IF 4.2) Pub Date : 2023-12-14 M.L. Gild, S. Kumar, T.L. Fuchs, A. Glover, S. Sidhu, M. Sywak, V. Tsang, A.J. Gill, B.G. Robinson, G. Schembri, R.J. Clifton Bligh, J. Hoang
Objectives Somatostatin receptor functional imaging with PET-CT has broadened the diagnostic and staging capabilities for medullary thyroid cancer (MTC). 68Ga-DOTATATE is a radiotracer with a high affinity for type 2 somatostatin receptors (SST2) expressed in many but not all MTCs. The utility of 68Ga-DOTATATE-PET/CT and 18F-FDG-PET/CT imaging in predicting MTC prognosis is also unknown. Methods In
-
Stroke prevention by anti-hyperglycemic drugs in type 2 diabetes mellitus. Endocr. Pract. (IF 4.2) Pub Date : 2023-12-13 Stewart G. Albert, Ekta Shrestha, Vaishaliben Ahir
Objectivess The American Heart Association/American Stroke Association and the American Association of Clinical Endocrinology provided guidelines for patients with transient ischemic attacks or strokes (TIA/Stroke) and diabetes mellitus (DM) with use of glucose-lowering agents (GLA) effective in preventing major adverse cardiovascular events (MACE). This review evaluated GLA for specific differences
-
The prognostic power of pre-ablation stimulated thyroglobulin in children with differentiated thyroid cancer Endocr. Pract. (IF 4.2) Pub Date : 2023-12-12 Farnaz Nesari Javan, Emran Askari, Susan Shafiei, Vahid Roshanravan, Atena Aghaei, Narjess Ayati, Seyed Rasoul Zakavi
Purpose To analyze prognostic factors in children with differentiated thyroid carcinoma (DTC) who have been treated in a single center in the last 27 years. Methods and patients We studied 126 children (≤18 years old) who have been treated with near-total thyroidectomy followed by radio-iodine therapy and thyroid hormone replacement. Follow-up of the patients was done 2, 6, and 12 months after treatment
-
Importance of Intraoperative Factors in Postoperative Arginine Vasopressin Deficiency after Pituitary Adenoma Surgery Endocr. Pract. (IF 4.2) Pub Date : 2023-12-11 Nasim Alidaei, Guive Sharifi, Zahra Davoudi
Objective Pituitary adenoma is the most frequent tumor in the sellar region. Arginine-vasopressin-deficiency (AVP-D), formerly known as central Diabetes-Insipidus (DI), is a common complication after pituitary surgeries. In this study, we reviewed patients with pituitary adenomas after endoscopic transsphenoidal surgery (ETSS), evaluated the incidence of postoperative AVP-D and determined associated
-
Corrigendum on “American Association of Clinical Endocrinology Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm - 2023 Update” Endocr. Pract. (IF 4.2) Pub Date : 2023-12-09
Abstract not available
-
Risk Of Gallstone Disease In Primary Hyperparathyroidism: A Systematic Review And Meta-Analysis Endocr. Pract. (IF 4.2) Pub Date : 2023-12-10 Rimesh Pal, Mainak Banerjee, Trupti N. Prasad, Ashok Kumar, Tushar Bhadada, Abhinav Vyas, Satinath Mukhopadhyay, Sanjay Kumar Bhadada
Objective Apart from renal stones, primary hyperparathyroidism (PHPT) has been linked to the occurrence of gallstone disease (GSD). Nevertheless, the association is not consistent across all studies. The present systematic review and meta-analysis aims to collate the hitherto available evidence and provide a pooled estimate of the association between GSD and PHPT. Methods PubMed/MEDLINE, Embase, and
-
Extended Treatment with rhPTH(1–84) in Adult Patients with Chronic Hypoparathyroidism Endocr. Pract. (IF 4.2) Pub Date : 2023-12-10 Mishaela R. Rubin, Natalie Cusano, Shaoming Yin, Elena Tokareva, Olulade Ayodele, Richard D. Finkelman
Objective Recombinant human parathyroid hormone (1–84) (rhPTH[1–84]) is efficacious in patients with hypoparathyroidism but additional data supporting its prolonged use are needed. We evaluated whether efficacy, safety, and tolerability are maintained during long-term rhPTH(1–84) treatment of patients with chronic hypoparathyroidism. Methods This was a phase 4, single-center, open-label, single-arm
-
The Ca*Cl/P ratio: a novel and more appropriate screening tool for normocalcaemic or overt primary hyperparathyroidism Endocr. Pract. (IF 4.2) Pub Date : 2023-12-10 Yanling Yu, Jingwen Qiu, Fengning Chuan, Zhengping Feng, Jian Long, Bo Zhou
Objective The main purpose of this study was to explore the diagnostic performance of the Ca*Cl/P ratio for primary hyperparathyroidism (PHPT), especially normocalcaemic primary hyperparathyroidism (NPHPT), to assist health-care providers in making reliable and rapid clinical identifications. Methods From January 1, 2013, to March 31, 2023, 230 PHPT patients, including 65 with NPHPT and 230 sex- and
-
Sodium-Glucose Cotransporter 2 Inhibitors Should Be Avoided for the Inpatient Management of Hyperglycemia Endocr. Pract. (IF 4.2) Pub Date : 2023-12-10 Benjamin Cohen MD, Yael Tobi Harris MD PhD, Rifka Schulman-Rosenbaum MD
Hyperglycemia in patients with type 2 diabetes mellitus is frequently encountered in the hospital setting. The recent guidelines for the management of inpatient hyperglycemia have included the use of dipeptidyl peptidase 4 inhibitors as an alternative to standard insulin therapy in select patients. This raises the question of the inpatient use of sodium-glucose cotransporter 2 inhibitors (SGLT2i),
-
Message from the Editor in Chief of Endocrine Practice: The Official Journal of the American Association of Endocrinology Endocr. Pract. (IF 4.2) Pub Date : 2023-12-10 Vin Tangpricha
Abstract not available
-
Info for Readers/Subscription page Endocr. Pract. (IF 4.2) Pub Date : 2023-12-09
Abstract not available
-
-
-
In Memoriam: Aaron I. Vinik, MD, PhD (1937 – 2023): The Quintessential Physician Scientist and Leader in Diabetic Neuropathy and Neuroendocrine Tumors Endocr. Pract. (IF 4.2) Pub Date : 2023-12-09 David C. Lieb, Henri K. Parson, Carolina M. Casellini, Elias S. Siraj
Abstract not available
-
-
Abnormal body composition increases the cardiometabolic risk in adolescents and young adults with Turner Syndrome Endocr. Pract. (IF 4.2) Pub Date : 2023-12-01 Sunetra Mondal, Piyas Gargari, Chiranjit Bose, Mahendra Kumar Garg, Subhankar Chowdhury, Satinath Mukhopadhyay
Objective To determine the cardio-metabolic risk of adolescents and adults with Turner Syndrome (TS) and find whether and how anthropometry and body composition predicts this risk Methods We compared anthropometric, biochemical, and dual-energy-X-ray-absorptiometry-(DXA)-derived body-composition parameters of 103 girls with TS (aged 12 – 30 years) and 103 controls of same age and BMI; between TS with
-
Lymph Node Ratio as a Predictive Factor of Persistent/Recurrent Disease in Patients with Medullary Thyroid Cancer: A Single-Centre Retrospective Study Endocr. Pract. (IF 4.2) Pub Date : 2023-11-25 Antonio Prinzi, Francesco Frasca, Marco Russo, Rosario Le Moli, Antonino Belfiore, Pasqualino Malandrino
Objective Thyroidectomy with neck lymph node dissection is curative for most patients with medullary thyroid cancer (MTC). Lymph node ratio (LNR, i.e., the ratio between the metastatic and the removed lymph nodes) is a reliable parameter with which to estimate both disease extent and quality of neck dissection. The aim of this study was to investigate the prognostic role of LNR to predict persistent/recurrent
-
Pulsatile Gonadotropin-Releasing Hormone Therapy Is Associated With Better Spermatogenic Outcomes than Gonadotropin Therapy in Patients With Pituitary Stalk Interruption Syndrome Endocr. Pract. (IF 4.2) Pub Date : 2023-11-28 Junyi Zhang, Yiyi Zhu, Rui Zhang, Hongying Liu, Bang Sun, Wei Zhang, Xi Wang, Min Nie, Jiangfeng Mao, Xueyan Wu
Objective To compare the effects of combined gonadotropin and pulsatile gonadotropin-releasing hormone (GnRH) therapy on spermatogenesis in patients with pituitary stalk interruption syndrome (PSIS). Methods Male patients with PSIS (N = 119) were retrospectively studied. Patients received pulsatile GnRH therapy (N = 59) were divided into response and poor-response groups based on luteinizing hormone
-
Clinical Characteristics of Adipsic Diabetes Insipidus Endocr. Pract. (IF 4.2) Pub Date : 2023-11-27 Tingjun Yang, Wei Wu, Xiaoyu Liu, Boni Xiang, Quanya Sun, Shuo Zhang, Yuan Zhuang, Zhiwen Yin, Qiongyue Zhang, Yanpei Cao, Hongying Ye
Objective Adipsic diabetes insipidus (ADI) is a life-threatening disease. It is characterized by arginine vasopressin deficiency and thirst absence. Data about clinical characteristics of ADI were scarce. This study investigated the clinical features of hospitalized ADI patients. Methods A retrospective study was conducted of hospitalized ADI patients admitted to the Endocrinology Department of Huashan